First Time Loading...

ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 65.48 USD 1.39% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. [ Read More ]

The intrinsic value of one ANIP stock under the Base Case scenario is 85.07 USD. Compared to the current market price of 65.48 USD, ANI Pharmaceuticals Inc is Undervalued by 23%.

Key Points:
ANIP Intrinsic Value
Base Case
85.07 USD
Undervaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ANI Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ANIP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
ANI Pharmaceuticals Inc

Provide an overview of the primary business activities
of ANI Pharmaceuticals Inc.

What unique competitive advantages
does ANI Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does ANI Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in ANI Pharmaceuticals Inc recently?

Summarize the latest earnings call
of ANI Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ANI Pharmaceuticals Inc.

Provide P/S
for ANI Pharmaceuticals Inc.

Provide P/E
for ANI Pharmaceuticals Inc.

Provide P/OCF
for ANI Pharmaceuticals Inc.

Provide P/FCFE
for ANI Pharmaceuticals Inc.

Provide P/B
for ANI Pharmaceuticals Inc.

Provide EV/S
for ANI Pharmaceuticals Inc.

Provide EV/GP
for ANI Pharmaceuticals Inc.

Provide EV/EBITDA
for ANI Pharmaceuticals Inc.

Provide EV/EBIT
for ANI Pharmaceuticals Inc.

Provide EV/OCF
for ANI Pharmaceuticals Inc.

Provide EV/FCFF
for ANI Pharmaceuticals Inc.

Provide EV/IC
for ANI Pharmaceuticals Inc.

Show me price targets
for ANI Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for ANI Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for ANI Pharmaceuticals Inc?

What are the Net Income projections
for ANI Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for ANI Pharmaceuticals Inc?

What are the EPS projections
for ANI Pharmaceuticals Inc?

How accurate were the past EPS estimates
for ANI Pharmaceuticals Inc?

What are the EBIT projections
for ANI Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for ANI Pharmaceuticals Inc?

Compare the revenue forecasts
for ANI Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ANI Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ANI Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of ANI Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of ANI Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing ANI Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of ANI Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for ANI Pharmaceuticals Inc.

Provide ROE
for ANI Pharmaceuticals Inc.

Provide ROA
for ANI Pharmaceuticals Inc.

Provide ROIC
for ANI Pharmaceuticals Inc.

Provide ROCE
for ANI Pharmaceuticals Inc.

Provide Gross Margin
for ANI Pharmaceuticals Inc.

Provide Operating Margin
for ANI Pharmaceuticals Inc.

Provide Net Margin
for ANI Pharmaceuticals Inc.

Provide FCF Margin
for ANI Pharmaceuticals Inc.

Show all solvency ratios
for ANI Pharmaceuticals Inc.

Provide D/E Ratio
for ANI Pharmaceuticals Inc.

Provide D/A Ratio
for ANI Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for ANI Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for ANI Pharmaceuticals Inc.

Provide Quick Ratio
for ANI Pharmaceuticals Inc.

Provide Current Ratio
for ANI Pharmaceuticals Inc.

Provide Cash Ratio
for ANI Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for ANI Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for ANI Pharmaceuticals Inc?

What is the current Free Cash Flow
of ANI Pharmaceuticals Inc?

Financials

Balance Sheet Decomposition
ANI Pharmaceuticals Inc

Current Assets 519.8m
Cash & Short-Term Investments 221.1m
Receivables 162.1m
Other Current Assets 136.6m
Non-Current Assets 384.6m
PP&E 44.6m
Intangibles 237.2m
Other Non-Current Assets 102.8m
Current Liabilities 145.5m
Accounts Payable 36.7m
Accrued Liabilities 57.8m
Other Current Liabilities 51m
Non-Current Liabilities 301.3m
Long-Term Debt 284.8m
Other Non-Current Liabilities 16.5m
Efficiency

Earnings Waterfall
ANI Pharmaceuticals Inc

Revenue
486.8m USD
Cost of Revenue
-181.5m USD
Gross Profit
305.3m USD
Operating Expenses
-257.2m USD
Operating Income
48.1m USD
Other Expenses
-32.6m USD
Net Income
15.5m USD

Free Cash Flow Analysis
ANI Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ANIP Profitability Score
Profitability Due Diligence

ANI Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
47/100
Profitability
Score

ANI Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

ANIP Solvency Score
Solvency Due Diligence

ANI Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
50/100
Solvency
Score

ANI Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ANIP Price Targets Summary
ANI Pharmaceuticals Inc

Wall Street analysts forecast ANIP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANIP is 81.4 USD with a low forecast of 77.77 USD and a high forecast of 87.15 USD.

Lowest
Price Target
77.77 USD
19% Upside
Average
Price Target
81.4 USD
24% Upside
Highest
Price Target
87.15 USD
33% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ANIP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ANIP Price
ANI Pharmaceuticals Inc

1M 1M
-4%
6M 6M
+14%
1Y 1Y
+65%
3Y 3Y
+98%
5Y 5Y
-5%
10Y 10Y
+112%
Annual Price Range
65.48
52w Low
37.29
52w High
69.69
Price Metrics
Average Annual Return -5.36%
Standard Deviation of Annual Returns 44.28%
Max Drawdown -73%
Shares Statistics
Market Capitalization 1.3B USD
Shares Outstanding 21 080 000
Percentage of Shares Shorted 1.22%

ANIP Return Decomposition
Main factors of price return

What is price return decomposition?

ANIP News

Last Important Events
ANI Pharmaceuticals Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
ANI Pharmaceuticals Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.3B USD

Dividend Yield

0%

Description

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

Contact

MINNESOTA
Baudette
210 W Main St
+12186343500.0
http://www.anipharmaceuticals.com/

IPO

2000-05-04

Employees

601

Officers

President, CEO & Director
Mr. Nikhil Lalwani
Senior VP of Finance & CFO
Mr. Stephen P. Carey
Senior Vice President of Operations & Product Development
Mr. James G. Marken
Head of Rare Disease
Mr. Christopher K. Mutz
Senior Vice President of Generics
Mr. Ori Gutwerg
Head of R&D, COO of Novitium Operations & Director
Mr. Muthusamy Shanmugam MS R.Ph.
Show More
Senior VP, General Counsel & Corporate Secretary
Ms. Meredith W. Cook
Senior Vice President of Corporate Development & Strategy
Mr. Chad Gassert
Chief Human Resources Officer
Ms. Krista L. Davis
Chief Compliance Officer & Head of Legal of Rare Disease
Ms. Elizabeth Powell J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ANIP stock?

The intrinsic value of one ANIP stock under the Base Case scenario is 85.07 USD.

Is ANIP stock undervalued or overvalued?

Compared to the current market price of 65.48 USD, ANI Pharmaceuticals Inc is Undervalued by 23%.